Moderna Stock Is at a Crossroads. Is the Path Ahead One of Profit or Pain for MRNA?

Moderna (MRNA), with its widely used COVID-19 vaccine, rose to prominence during the global pandemic. The stock soared an eye-catching 838.4% between 2020 and 2022. 

But the company is now stepping into a new era to prove that its mRNA technology can deliver beyond COVID-19. With new vaccine approvals, an expanding pipeline, and ambitious bets on cancer and artificial intelligence, the company is attempting to reinvent itself. But as coronavirus sales fade and competition grows, the question arises whether Moderna’s comeback is built on real progress or just renewed hype.